Last year, the FDA approved the first non-hormonal treatment for hot flashes – a 7.5-mg formulation of the selective serotonin reuptake inhibitor (SSRI) paroxetine which was marketed under the name of Brisdelle. A new study [...]
Current research suggests that women with premenstrual dysphoric disorder (PMDD) have an abnormal affective response to normal hormonal shifts that occur during the menstrual cycle. Some researchers have hypothesized a metabolite of progesterone (PROG), allopregnanolone [...]
Benzodiazepines and non-benzodiazepine hypnotics are commonly used during pregnancy. However, there data regarding the reproductive safety of these agents has been somewhat mixed. Although initial reports suggested that there may be an increased risk of cleft lip and palate, more recent reports have shown no association between exposure to benzodiazepines and risk for cleft lip or palate. A new study shows no increase in the overall risk of malformations among children exposed to benzodiazepines.
When women come to us for consultation, we focus primarily on the risks of exposure to psychotropic medications. It is important, however, to consider the impact of other, potentially harmful, exposures that are common in [...]
Research from the CWMH: For Menopausal Women Venlafaxine Does Not Appear to Affect Sexual Functioning
While many midlife women are interested in pursuing non-hormonal options for the treatment of menopausal symptoms, they are understandably concerned about taking antidepressant medications, such as SSRIs and SNRIs, that, while effective for treating hot [...]
A significant number of women experience anxiety symptoms during pregnancy, with nearly 10% of women meeting criteria for generalized anxiety disorder. Even more women suffer from milder anxiety symptoms or what some refer to as [...]
In this study 62 women hospitalized for high-risk obstetrical complications completed the Edinburgh Postnatal Depression Scale (EPDS), Generalized Anxiety Disorder 7-item scale (GAD-7), and Short-Form 12 (SF-12) weekly until delivery or discharge and once after [...]
This is the second part of a two part series on the use of antipsychotic medications during pregnancy. Read Part 1 here, which reviews data from the Australian antipsychotic registry.
A recent study of 2507 menopausal women suggests that menopausal women with higher caffeine intake are more likely to have hot flashes and night sweats; however, they have fewer problems with mood, memory, and concentration. [...]
A recent study followed 29 mothers who gave birth to 35 premature children born before the 33rd week of pregnancy. The women were assessed within 2 weeks postpartum (T0), 2 weeks after hospitalization (T1), 6 months post-term (T2), and 18 months post-term (T3). The Impact of Event Scale (IES), General Health Questionnaire (GHQ) and State Anxiety Inventory (STAI-X1) were used to assess maternal mental health outcomes.